tetano
Editor, Senior Moderator
Int J Chron Obstruct Pulmon Dis
. 2024 Nov 14:19:2421-2430.
doi: 10.2147/COPD.S479968. eCollection 2024. Clinical Characteristics and Outcomes of Hospitalized AECOPDs Secondary to SARS-CoV-2 versus Other Respiratory Viruses
Louis Chhor[SUP] 1 2 [/SUP], Stefan Saggese[SUP] 2 [/SUP], Garun S Hamilton[SUP] 1 3 [/SUP], Martin Ian MacDonald[SUP] 1 [/SUP]
Affiliations
Objective: To compare clinical characteristics and outcomes of hospitalized acute exacerbations of COPD (AECOPD)s secondary to SARS-CoV-2 versus other respiratory viruses amongst a highly vaccinated population in the Omicron era.
Design: Retrospective cohort study; analysis of hospital medical records and linked pathology and radiology reports.
Setting: Tertiary health network in Victoria, Australia; January 2022-August 2022.
Main outcome measures: Key clinical information including comorbidities, vaccination status, treatments administered and outcomes such as hospital length of stay, ICU admission, non-invasive ventilation usage and inpatient mortality.
Results: One hundred ninety-nine viral AECOPDs - 125 SARS-CoV-2 and 74 other viruses were identified. Of the SARS-CoV-2 group. 13.6% were unvaccinated, 17.6% partially and 68.0% fully vaccinated. The SARS-CoV-2 group were older (77.2 vs 68.9, p < 0.00001) with more comorbidities (1[1-2] vs 1[0-2], p = 0.008) and lower candidacy for full resuscitation (25.6% vs 56.8%, p < 0.0001). Mortality tended to be higher among SARS-CoV2 admission (9.6% v 2.7%, p = 0.066) but rates of ICU admission (10.4% v 13.5%, p = 0.507), length of hospitalisation (5[3-8] vs 5[3-9], p = 0.9) and readmission within 30 days (25% vs 33.3%, p = 0.184) were similar.
Conclusion: In a highly vaccinated population in the Omicron era, COPD patients requiring hospitalisation with SARS-CoV-2 are older with more comorbidities than those admitted with other respiratory viruses. Length of hospitalisation and ICU utilisation was similar. Inpatient mortality may be higher.
Keywords: COPD; SARS-CoV2; coronavirus; viral exacerbations.
. 2024 Nov 14:19:2421-2430.
doi: 10.2147/COPD.S479968. eCollection 2024. Clinical Characteristics and Outcomes of Hospitalized AECOPDs Secondary to SARS-CoV-2 versus Other Respiratory Viruses
Louis Chhor[SUP] 1 2 [/SUP], Stefan Saggese[SUP] 2 [/SUP], Garun S Hamilton[SUP] 1 3 [/SUP], Martin Ian MacDonald[SUP] 1 [/SUP]
Affiliations
- PMID: 39559372
- PMCID: PMC11572465
- DOI: 10.2147/COPD.S479968
Objective: To compare clinical characteristics and outcomes of hospitalized acute exacerbations of COPD (AECOPD)s secondary to SARS-CoV-2 versus other respiratory viruses amongst a highly vaccinated population in the Omicron era.
Design: Retrospective cohort study; analysis of hospital medical records and linked pathology and radiology reports.
Setting: Tertiary health network in Victoria, Australia; January 2022-August 2022.
Main outcome measures: Key clinical information including comorbidities, vaccination status, treatments administered and outcomes such as hospital length of stay, ICU admission, non-invasive ventilation usage and inpatient mortality.
Results: One hundred ninety-nine viral AECOPDs - 125 SARS-CoV-2 and 74 other viruses were identified. Of the SARS-CoV-2 group. 13.6% were unvaccinated, 17.6% partially and 68.0% fully vaccinated. The SARS-CoV-2 group were older (77.2 vs 68.9, p < 0.00001) with more comorbidities (1[1-2] vs 1[0-2], p = 0.008) and lower candidacy for full resuscitation (25.6% vs 56.8%, p < 0.0001). Mortality tended to be higher among SARS-CoV2 admission (9.6% v 2.7%, p = 0.066) but rates of ICU admission (10.4% v 13.5%, p = 0.507), length of hospitalisation (5[3-8] vs 5[3-9], p = 0.9) and readmission within 30 days (25% vs 33.3%, p = 0.184) were similar.
Conclusion: In a highly vaccinated population in the Omicron era, COPD patients requiring hospitalisation with SARS-CoV-2 are older with more comorbidities than those admitted with other respiratory viruses. Length of hospitalisation and ICU utilisation was similar. Inpatient mortality may be higher.
Keywords: COPD; SARS-CoV2; coronavirus; viral exacerbations.